Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer

Urology

Volumn 53, Issue 5, 1999, Pages 898-902

  Hall, M Craig ^a,b   Fritzsch, Ralph J ^a,b   Sagalowsky, Arthur I ^a,b   Ahrens, Allison ^a,b   Petty, Beth ^a,b   Roehrborn, Claus G ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Section of Urology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; ADVANCED CANCER; AGED; ANTIGEN DETECTION; ARTICLE; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MIXTURE; DRUG WITHDRAWAL; HORMONAL THERAPY; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; LUTEINIZING HORMONE BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TESTOSTERONE BLOOD LEVEL;

EID: 0033009276     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00061-8     Document Type: Article

References (14)

1. Soloway MS, Chodak G, Vogelzang NJ, et al, Zoladex Prostate Study Group: Zoladex vs orchiectomy in treatment of advanced prostate cancer: a randomized trial. Urology 37: 46-51, 1991.
2. DeBruyne F.M., Dijkman G.A., Lee D.C.H., et al. A new long acting formulation of the luteinizing hormone-releasing hormone analogue, goserelin results of studies in prostate cancer . J Urol. 155:1996;1352-1354.
3. Health Care Financing Administration: BESS procedure data, 1996.
4. Akakura K., Bruchovsky N., Goldenberg S.L., et al. Effects of intermittent androgen suppression on androgen-dependent tumors. Cancer. 71:1993;2782-2790.
5. Goldenberg S.L., Bruchovsky N., Gleave M.E., et al. Intermittent androgen suppression in the treatment of prostate cancer a preliminary report . Urology. 45:1995;839-845.
6. Pilepich M.V., Sause W.T., Shipley W.U., et al. Androgen deprivation with radiation therapy compared with radiotherapy alone for locally advanced prostate cancer a randomized comparative trial of the radiation therapy oncology group . Urology. 45:1995;616-622.
7. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300.
8. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformed radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
9. McLeod D.G., Johnson C.F., Klein E., et al. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. Urology. 49:(suppl 3A):1997;70-73.
10. 2 prostate cancer interim results of a prospective randomized trial . J Urol. 154:1995;429-434.
11. Oefelein M.G. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting implications for dosing schedule and neoadjuvant study consideration . J Urol. 160:1998;1685-1688.
12. Robinson M.R., Thomas B.S. Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma. BMJ. 4:1971;391-394.
13. Tomic R., Bergman B. Hormonal effects of cessation of estrogen treatment for prostatic carcinoma. J Urol. 138:1987;801-805.
14. Maatman T.J., Gupta M.K., Montie J.E. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate. J Urol. 133:1985;620-621.